Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.

EP: 1.Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP: 2.Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP: 3.Outcomes from NATALEE and MonarchE

EP: 4.Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP: 5.Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

EP: 6.Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

EP: 7.Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

EP: 8.Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

EP: 9.Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

EP: 10.How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

EP: 11.Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Now Viewing

EP: 12.Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

EP: 13.ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

• How does the use of CDK4/6 inhibitors in this space contribute to the total cost of care for breast cancer, and what cost containment strategies can we consider adopting?

Related Videos

Related Content

Advertisement

June 2nd 2025

Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

Rose McNulty

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

March 27th 2025

Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

Cameron Santoro

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for risk-based screening strategies that account for factors like breast density, hormone replacement therapy, and family cancer history to improve early detection.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

February 17th 2025

Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

Pearl Steinzor

Racial and ethnic disparities were identified in immunotherapy receipt for Black patients with metastatic triple-negative breast cancer.

February 13th 2025

TILs May Guide Treatment De-Escalation in ERBB2-Positive Breast Cancer

Pearl Steinzor

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit from shorter trastuzumab and chemotherapy regimens.

Related Content

Advertisement

June 2nd 2025

Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

Rose McNulty

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

March 27th 2025

Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

Cameron Santoro

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for risk-based screening strategies that account for factors like breast density, hormone replacement therapy, and family cancer history to improve early detection.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

February 17th 2025

Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

Pearl Steinzor

Racial and ethnic disparities were identified in immunotherapy receipt for Black patients with metastatic triple-negative breast cancer.

February 13th 2025

TILs May Guide Treatment De-Escalation in ERBB2-Positive Breast Cancer

Pearl Steinzor

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit from shorter trastuzumab and chemotherapy regimens.